Released Aug 3, 2012, after the close
10-Q filed Aug 3, 2012, 34 days after period end · 0001144204-12-042862
Q2 2012 · 10-Q
Revenue$26.11M$26.11M +3,317.9% vs Q2 2011+576.3% vs Q1 2012
Net Income$9.64M$9.64M N/M vs Q2 2011N/M vs Q1 2012
EPS Diluted$0.10$0.10 N/M vs Q2 2011+42.9% vs Q1 2012
Gross Profit$21,979,000N/M
Operating Income$9,620,000N/M
Operating Cash Flowderived$13,124,000N/M
Free Cash Flowderived$12,887,000N/M
Margins · derived
Gross margin84.2%+705.9 pt vs Q2 2011
Operating margin36.8%+1852.0 pt vs Q2 2011
Net margin36.9%+1828.7 pt vs Q2 2011
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q2 2012 | Q2 2011 | Q2 2010 |
|---|---|---|---|
| Revenue | $26.11M | $764.00K | $1.14M |
| Net Income | $9.64M | -$13.69M | -$10.04M |
| EPS Diluted | $0.10 | -$0.16 | $0.12 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR